Expand all sections

Bomedemstat

Extended indication Essential thrombocythaemia and myelofibrosis.
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Bomedemstat
Domain Hematology
Reason of inclusion New medicine (specialité)
Main indication Myeloproliferative disorders
Extended indication Essential thrombocythaemia and myelofibrosis.
Manufacturer Imago
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)
Additional remarks Lysine specific demethylase 1 inhibitor.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2023
Expected Registration 2024
Orphan drug Yes
Registration phase Clinical trials

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times a day
References NCT05223920

Expected patient volume per year

Patient volume

< 166

Market share is generally not included unless otherwise stated.
References NKR 2018 (1);
Additional remarks In totaal waren er 166 diagnoses in 2018 (1).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.